Otsuka Pays Price As AVP-786 Dropped For Alzheimer's Agitation

Follows Setbacks In Other Uses

 
• By Lisa Takagi

Otsuka has now formally decided to terminate the development of AVP-786 for Alzheimer's agitation, for which it is set to book another JPY100bn loss this year, and marking a major setback for an asset that was a key attraction in a previous large acquisition.

Otsuka has already recorded JPY105.5bn loss from AVP-786's P3 fail in the previous year.
Otsuka already booked JPY105.5bn loss in 2023 from AVP-786 failures • Source: Shutterstock

More from R&D

More from Scrip